Micron Biomedical Secures Series A Financing to Commercialize MAP Technology for Self-Administration of Drugs and Vaccines without Needles – Yahoo Finance

Global Health Investment Corporation and LTS Lohmann Led the Series A Financing with Participation from GRA Venture Fund
ATLANTA, Nov. 28, 2022 /PRNewswire/Micron Biomedical, Inc. is a clinical stage life sciences company advancing its Micro Array Patch (MAP) technology for self-administration and simple, less-skilled caregiver administration of drugs and vaccines without needles. The $14 million Series A financing will support the company’s development of commercial manufacturing, currently underway and establishes a strong partnership between Micron and LTS Lohmann. Micron’s development pipeline includes vaccine and drug products partnered with pharma companies, foundations, and government agencies. Since inception, Micron has supported its R&D activities and shown clinical efficacy with more than $40 million in non-dilutive financing.
“Micron’s technology has the potential to change the way we administer many of today’s currently injected drugs and vaccines” said Micron CEO Steven Damon. “We are deeply committed to bringing Micron’s MAP technology-based drug and vaccine products to market, improving access and having a positive impact on patients globally. This financing, and in particular our new investors, will help us to achieve our goals”.
Micron’s MAP technology is well suited to delivering a wide range of compounds including nucleic acids, peptides, proteins, and viruses (inactivated and live-attenuated), as well as small-molecule drugs. The benefits of Micron’s MAP technology include the potential to enhance the efficacy of drugs and vaccines, ease-of-use enabling self-administration and administration by less skilled caregivers, sharps-free waste, thermal stability and small size, which together simplify storage and distribution with the potential to have products mailed to people’s homes or available to pick up at the pharmacy without needing a professional to administer. These benefits render Micron’s MAP technology especially desirable in case of a pandemic.
About Micron Biomedical
Micron is an Atlanta-based company whose MAP technology was initially developed in Dr. Mark Prausnitz’s labs at Georgia Tech. Micron has further developed the technology and emerged as a leader in the field of dissolvable microarray-based, drug and vaccine delivery technology. In addition to these new investors, Micron’s other partners and funders include the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), UNICEF, PATH and several private and public undisclosed pharmaceutical companies. Micron has also received support from the Georgia Research Alliance.
LTS LOHMANN Therapie-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches (MAP) for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from three sites: in Andernach, Germany, West Caldwell, NJ, USA and St. Paul, MN, USA. LTS has also a representative office in Shanghai, China.
About Global Health Investment Corporation
A pioneer of investing in global health, GHIC has been supporting high impact biomedical innovations for nearly a decade. GHIC’s Global Health Investment Fund (GHIF) financed the development of products to combat public health challenges that disproportionately affect people living in low- and middle-income countries. In 2021, GHIC entered into a 10-year venture investment partnership with the Biomedical Advanced Research and Development Authority (BARDA) focused on global health security.
For more information visit: www.micronbiomedical.com
For IR / Media / Partnering: 
View original content:https://www.prnewswire.com/news-releases/micron-biomedical-secures-series-a-financing-to-commercialize-map-technology-for-self-administration-of-drugs-and-vaccines-without-needles-301687431.html
SOURCE Micron Biomedical, Inc.
Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.
(Bloomberg) — Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsThere’s a Job-Market Riddle at the Heart of the Next RecessionThe case involved a 65-year-old woman who died of a massive brain hemorrhage
What happened Shares of Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biotech that specializes in therapies to treat neurodegenerative and neurodevelopmental diseases, fell by 23.5% on Monday.
Axsome Therapeutics said its Alzheimer's treatment met the goals of a study, sending its shares into the stratosphere, while Biogen's Alzheimer's effort had a setback.
Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.
Is Pfizer stock a buy after surging on Moderna's omicron-focused booster shot data? Is PFE stock a buy right now?
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
As AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be the middlemen negotiating and dispensing the drugs such as Cigna and CVS.
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that some researchers link to the drug. Clinical trial death is the second thought associated with the lecanemab. STAT recently reported that an 80-year-old man in lecanemab's phase 3 trial died of a brain hemorrhage linked to the possible interaction between the experimental antibody and the blood thinne
Rising interest rates and a looming recession that those higher rates could cause are weighing heavily on stock prices across the board. Shares of Biogen (NASDAQ: BIIB) have been on a roller coaster over the past couple of years. The stock rocketed higher in 2021 after the FDA granted a highly controversial approval to the company's Alzheimer's disease drug, Aduhelm.
Here's what you should ideally set your heating to and how to use it in the most effective way.
The global licensing deal also includes exclusive rights for other undisclosed inflammatory and respiratory diseases.
Shares of CinCor Pharma Inc. fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed to meet the primary endpoint in a Phase 2 clinical trial. CinCor said it still plans to meet with the Food and Drug Administration in January to discuss plans for its Phase 3 program for baxdrostat. The company's stock is down 29.8% over the past three months, while the S&P 500 has declined 4.1%.
The consumer price index increased 7.7% year over year in October, a solid signal that the inflation rate is now trending in the right direction. The pharma stock Eli Lilly (NYSE: LLY) is chief among these stocks. Let's take a look under the hood at Eli Lilly's fundamentals and valuation to decide.
According to a U.K. trial, Eliquis (apixaban), widely prescribed for COVID-19, did not help patients recovering from moderate and severe COVID. The drug used after discharge from the hospital does not lessen the chances for COVID-19 patients of readmission or improve survival. The results were shared with the Financial Times. Eliquis is indicated to reduce the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat. Related: National Institute
Marijuana is both a threat and a hazard. Legalization is an extremely unwise policy.
Eating potatoes can help people lose weight, according to a new study.
Anthony Fauci says United States is 'certainly' still in COVID-19 pandemic
Patrick Swayze, the husband of Lisa Niemi Swayze who starred in "Dirty Dancing” and Ghost," passed away in 2009 from advanced pancreatic cancer. He was 57.


Add a Comment

Your email address will not be published. Required fields are marked *